The key products and services being delivered under this federal contract Indefinite Delivery Vehicle (IDV) are PYLARIFY (piflufolastat F-18), a radiopharmaceutical used for positron emission tomography (PET) imaging to detect, localize, and image prostate cancer. The prime contractor is Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc. The Department of Veterans Affairs (VA) and Defense Health Agency (DHA) are the primary funding agencies, with the VA procuring PYLARIFY for use at its medical facilities nationwide. Several delivery order contracts and Blanket Purchase Agreements (BPAs), valued from under $100,000 to over $5 million, have been awarded to Progenics Pharmaceuticals to supply PYLARIFY and support the VA and military healthcare programs' prostate cancer detection and treatment efforts. These contracts, issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), do not utilize any set-aside designations. The performance locations are primarily in Massachusetts, with some orders fulfilled in other states. The periods of performance typically range from one to five years, ensuring a steady supply of this critical radiopharmaceutical to government healthcare providers.
In addition to the delivery order contracts, Progenics Pharmaceuticals holds several significant BPAs with the VA and DHA, valued up to $5.5 million, that facilitate the ongoing procurement of PYLARIFY and other radiopharmaceuticals for cancer detection and treatment at VA medical centers and military treatment facilities. These BPAs, which are also associated with the Pharmaceuticals and Drugs FSS-61-IB contract, streamline the ordering process and guarantee access to these specialized diagnostic agents for federal healthcare programs. Some of the BPAs have a total small business set-aside designation, while others are unrestricted.
Generated 11/20/24, 9:05 AM